Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

Volume: 76, Issue: 1, Pages: 60 - 69.e9
Published: Jan 1, 2017
Abstract
Background Secukinumab demonstrated superior efficacy to ustekinumab at week 4 and week 16 of the CLEAR study, with comparable safety, in subjects with moderate-to-severe plaque psoriasis. Objective To compare the efficacy and safety of secukinumab and ustekinumab use over 52 weeks. Methods Analysis of 52-week data from CLEAR, a randomized, double-blind, phase 3b study. Results Among 676 randomized subjects, secukinumab demonstrated superiority...
Paper Details
Title
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Published Date
Jan 1, 2017
Volume
76
Issue
1
Pages
60 - 69.e9
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.